Clinical Trial Update: First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial of PhOx430, a first-in-class Acetylglucosaminyltransferase V inhibitor, assessed in advanced solid tumors; the study is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Glioblastoma
• Solid Tumors

Drugs mentioned

• PhOx430

Snippet

Sponsor: Phost'In Therapeutics | Conditions: Malignant Tumor, Advanced Solid Tumor | Phase 1 | Status: RECRUITING